109 related articles for article (PubMed ID: 29343281)
1. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
[TBL] [Abstract][Full Text] [Related]
2. Expression and function of Toll-like receptors in peripheral blood mononuclear cells from patients with ovarian cancer.
Zhang X; Xu J; Ke X; Zhang S; Huang P; Xu T; Huang L; Lou J; Shi X; Sun R; Wang F; Pan S
Cancer Immunol Immunother; 2015 Mar; 64(3):275-86. PubMed ID: 25376541
[TBL] [Abstract][Full Text] [Related]
3. Phyllanthusmin Derivatives Induce Apoptosis and Reduce Tumor Burden in High-Grade Serous Ovarian Cancer by Late-Stage Autophagy Inhibition.
Young AN; Herrera D; Huntsman AC; Korkmaz MA; Lantvit DD; Mazumder S; Kolli S; Coss CC; King S; Wang H; Swanson SM; Kinghorn AD; Zhang X; Phelps MA; Aldrich LN; Fuchs JR; Burdette JE
Mol Cancer Ther; 2018 Oct; 17(10):2123-2135. PubMed ID: 30018048
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor expression in normal ovary and ovarian tumors.
Zhou M; McFarland-Mancini MM; Funk HM; Husseinzadeh N; Mounajjed T; Drew AF
Cancer Immunol Immunother; 2009 Sep; 58(9):1375-85. PubMed ID: 19184006
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of prexasertib monotherapy in recurrent
Lampert EJ; Cimino-Mathews A; Lee JS; Nair J; Lee MJ; Yuno A; An D; Trepel JB; Ruppin E; Lee JM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32709712
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-10 in serous ovarian carcinoma cell lines.
Berger S; Siegert A; Denkert C; Köbel M; Hauptmann S
Cancer Immunol Immunother; 2001 Aug; 50(6):328-33. PubMed ID: 11570587
[TBL] [Abstract][Full Text] [Related]
7. The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer.
Ou T; Lilly M; Jiang W
Front Immunol; 2018; 9():1188. PubMed ID: 29928275
[TBL] [Abstract][Full Text] [Related]
8. Curcumin Nanoparticle Enhances the Anticancer Effect of Cisplatin by Inhibiting PI3K/AKT and JAK/STAT3 Pathway in Rat Ovarian Carcinoma Induced by DMBA.
Sandhiutami NMD; Arozal W; Louisa M; Rahmat D; Wuyung PE
Front Pharmacol; 2020; 11():603235. PubMed ID: 33536913
[TBL] [Abstract][Full Text] [Related]
9. Curcumin Ameliorates Cisplatin-Induced Nephrotoxicity and Potentiates Its Anticancer Activity in SD Rats: Potential Role of Curcumin in Breast Cancer Chemotherapy.
Kumar P; Barua CC; Sulakhiya K; Sharma RK
Front Pharmacol; 2017; 8():132. PubMed ID: 28420987
[TBL] [Abstract][Full Text] [Related]
10. Limitations and potential of immunotherapy in ovarian cancer.
Kumar S; Acharya S; Karthikeyan M; Biswas P; Kumari S
Front Immunol; 2023; 14():1292166. PubMed ID: 38264664
[TBL] [Abstract][Full Text] [Related]
11. Polyarginine induces an antitumor immune response through binding to toll-like receptor 4.
Yang Y; Wolfram J; Fang X; Shen H; Ferrari M
Small; 2014 Apr; 10(7):1250-4. PubMed ID: 24323884
[TBL] [Abstract][Full Text] [Related]
12. Highly Active Myeloid Therapy for Cancer.
Fredrich IR; Halabi EA; Kohler RH; Ge X; Garris CS; Weissleder R
ACS Nano; 2023 Oct; 17(20):20666-20679. PubMed ID: 37824733
[TBL] [Abstract][Full Text] [Related]
13. RNA-Peptide nanoplexes drug DNA damage pathways in high-grade serous ovarian tumors.
Dreaden EC; Kong YW; Quadir MA; Correa S; Suárez-López L; Barberio AE; Hwang MK; Shi AC; Oberlton B; Gallagher PN; Shopsowitz KE; Elias KM; Yaffe MB; Hammond PT
Bioeng Transl Med; 2018 Jan; 3(1):26-36. PubMed ID: 29376131
[TBL] [Abstract][Full Text] [Related]
14. P-MAPA activates TLR2 and TLR4 signaling while its combination with IL-12 stimulates CD4+ and CD8+ effector T cells in ovarian cancer.
Silveira HS; Lupi LA; Romagnoli GG; Kaneno R; da Silva Nunes I; Fávaro WJ; de Almeida Chuffa LG
Life Sci; 2020 Aug; 254():117786. PubMed ID: 32433918
[TBL] [Abstract][Full Text] [Related]
15. P-MAPA and Interleukin-12 Reduce Cell Migration/Invasion and Attenuate the Toll-Like Receptor-Mediated Inflammatory Response in Ovarian Cancer SKOV-3 Cells: A Preliminary Study.
Lupi LA; Delella FK; Cucielo MS; Romagnoli GG; Kaneno R; Nunes IDS; Domeniconi RF; Martinez M; Martinez FE; Fávaro WJ; Chuffa LGA
Molecules; 2019 Dec; 25(1):. PubMed ID: 31861351
[TBL] [Abstract][Full Text] [Related]
16. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
[TBL] [Abstract][Full Text] [Related]
17. P-MAPA, a Fungi-Derived Immunomodulatory Compound, Induces a Proinflammatory Response in a Human Whole Blood Model.
Gonçalves MT; Squaiella-Baptistão CC; Pidde G; Lopes PH; da Silva Nunes I; Tambourgi DV
Mediators Inflamm; 2020; 2020():8831389. PubMed ID: 33299378
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis.
Lau TS; Chan LKY; Man GCW; Wong CH; Lee JHS; Yim SF; Cheung TH; McNeish IA; Kwong J
Cancer Immunol Res; 2020 Aug; 8(8):1099-1111. PubMed ID: 32354736
[TBL] [Abstract][Full Text] [Related]
19. The role of Toll-like receptor 4 signaling pathway in ovarian, cervical, and endometrial cancers.
Lupi LA; Cucielo MS; Silveira HS; Gaiotte LB; Cesário RC; Seiva FRF; de Almeida Chuffa LG
Life Sci; 2020 Apr; 247():117435. PubMed ID: 32081661
[TBL] [Abstract][Full Text] [Related]
20. TLR4 blockade using TAK-242 suppresses ovarian and breast cancer cells invasion through the inhibition of extracellular matrix degradation and epithelial-mesenchymal transition.
Zandi Z; Kashani B; Poursani EM; Bashash D; Kabuli M; Momeny M; Mousavi-Pak SH; Sheikhsaran F; Alimoghaddam K; Mousavi SA; Ghaffari SH
Eur J Pharmacol; 2019 Jun; 853():256-263. PubMed ID: 30930249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
